Celexa/Lexapro MDL winds up
Celexa/Lexapro MDL winds up
Introduction
The U.S. District Judge Nathaniel M. Gorton granted Forest Laboratories’ motion for summary judgment on all claims made by the plaintiffs who alleged that the company fraudulently promoted Celexa and Lexapro for pediatric depression. This ruling brings an end to the long-running Massachusetts MDL 2067: In Re: Celexa and Lexapro Marketing and Sales Practices Litigation.
Comments
Latest News
Zimmer Biomet Gets FDA Approval for Cementless Partial Knee
Categories: Zimmer Hip/Knee Replacement
Zimmer Biomet announced it has received supplemental FDA premarket approval (PMA) for the Oxford Cementless Partial…
Court Names Special Masters for Bard Mesh Claim Settlements
Categories: Hernia Mesh
The U.S. District Judge overseeing the federal litigation involving Bard hernia mesh lawsuits has appointed two…
Baltimore Wins $266M in Opioid Case Against Drug Distributors
Categories: Opioids
Baltimore has secured a $266 million victory in its lawsuit against major drug distributors McKesson and Cencora (formerly AmerisourceBergen), accusing them of fueling the…